Biomerica, Inc. (NASDAQ:BMRA) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.73 and traded as low as $3.17. Biomerica shares last traded at $3.19, with a volume of 4,522 shares traded.
Separately, B. Riley set a $6.00 price target on shares of Biomerica and gave the stock a “buy” rating in a research report on Tuesday, September 10th.
The firm’s 50-day moving average is $3.05 and its two-hundred day moving average is $2.73. The stock has a market cap of $31.52 million, a price-to-earnings ratio of -12.12 and a beta of 1.45.
An institutional investor recently bought a new position in Biomerica stock. Susquehanna International Group LLP acquired a new stake in Biomerica, Inc. (NASDAQ:BMRA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 17,688 shares of the company’s stock, valued at approximately $46,000. Susquehanna International Group LLP owned about 0.18% of Biomerica at the end of the most recent quarter. Hedge funds and other institutional investors own 1.22% of the company’s stock.
Biomerica Company Profile (NASDAQ:BMRA)
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.